CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $1.98 billion. The enterprise value is $1.29 billion.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 76.23 million shares outstanding. The number of shares has increased by 1,511.14% in one year.
| Current Share Class | 76.23M |
| Shares Outstanding | 76.23M |
| Shares Change (YoY) | +1,511.14% |
| Shares Change (QoQ) | +10.33% |
| Owned by Insiders (%) | 0.68% |
| Owned by Institutions (%) | 89.97% |
| Float | 61.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,987.99 |
| Forward PS | n/a |
| PB Ratio | 2.84 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,949.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.97, with a Debt / Equity ratio of 0.00.
| Current Ratio | 30.97 |
| Quick Ratio | 30.42 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.57% and return on invested capital (ROIC) is -13.18%.
| Return on Equity (ROE) | -16.57% |
| Return on Assets (ROA) | -12.85% |
| Return on Invested Capital (ROIC) | -13.18% |
| Return on Capital Employed (ROCE) | -19.05% |
| Revenue Per Employee | $5,858 |
| Profits Per Employee | -$934,133 |
| Employee Count | 113 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.97% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.97% |
| 50-Day Moving Average | 25.21 |
| 200-Day Moving Average | 29.51 |
| Relative Strength Index (RSI) | 50.83 |
| Average Volume (20 Days) | 833,898 |
Short Selling Information
The latest short interest is 11.08 million, so 14.53% of the outstanding shares have been sold short.
| Short Interest | 11.08M |
| Short Previous Month | 12.34M |
| Short % of Shares Out | 14.53% |
| Short % of Float | 18.12% |
| Short Ratio (days to cover) | 12.43 |
Income Statement
In the last 12 months, CG Oncology had revenue of $662,000 and -$105.56 million in losses. Loss per share was -$1.51.
| Revenue | 662,000 |
| Gross Profit | -91.70M |
| Operating Income | -134.40M |
| Pretax Income | n/a |
| Net Income | -105.56M |
| EBITDA | -134.35M |
| EBIT | -134.40M |
| Loss Per Share | -$1.51 |
Full Income StatementBalance Sheet
The company has $688.43 million in cash and $1.04 million in debt, giving a net cash position of $687.40 million or $9.02 per share.
| Cash & Cash Equivalents | 688.43M |
| Total Debt | 1.04M |
| Net Cash | 687.40M |
| Net Cash Per Share | $9.02 |
| Equity (Book Value) | 704.76M |
| Book Value Per Share | 9.25 |
| Working Capital | 678.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.98 million and capital expenditures -$238,000, giving a free cash flow of -$82.22 million.
| Operating Cash Flow | -81.98M |
| Capital Expenditures | -238,000 |
| Free Cash Flow | -82.22M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -20,302.27% |
| Pretax Margin | -15,945.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,511.14% |
| Shareholder Yield | -1,511.14% |
| Earnings Yield | -5.34% |
| FCF Yield | -4.16% |
Analyst Forecast
The average price target for CG Oncology is $64.44, which is 148.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $64.44 |
| Price Target Difference | 148.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 271.50% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CG Oncology has an Altman Z-Score of 58.65 and a Piotroski F-Score of 4.
| Altman Z-Score | 58.65 |
| Piotroski F-Score | 4 |